Camurus, Eli Lilly Collaborate for Long-Acting Incretin Products Using FluidCrystal Technology

On Tuesday, Camurus (OTC:CAMRF) and Eli Lilly and Company (NYSE:LLY) entered into a collaboration and license agreement. This agreement grants Lilly exclusive, worldwide rights to research, develop, manufacture, and commercialize long-acting incretin products for cardiometabolic health, using Camurus’ proprietary FluidCrystal technology.

The partnership will encompass up to 4 of Lilly’s proprietary drug compounds, which may include dual GIP and GLP-1 receptor agonists, triple GIP, glucagon and GLP-1 receptor agonists, and potentially amylin receptor agonists. Under the terms of the agreement, Camurus is eligible to receive up to $290 million in upfront, development, and regulatory milestone payments. Additionally, Camurus stands to receive up to $580 million in sales-based milestone payments and tiered mid-single-digit royalties on global net product sales.

The collaboration allows Camurus to use its FluidCrystal technology in the expanding indication areas that impact hundreds of millions of people, while maintaining its commercial focus on Central Nervous System and rare diseases. The FluidCrystal technology is designed to deliver therapeutic levels of drug substance over extended periods via a single injection using a prefilled syringe or autoinjector pen. Upon contact with bodily fluids, the lipid solution transforms into a liquid crystalline gel that encapsulates and slowly releases the active ingredient as the matrix degrades.

Camurus (OTC:CAMRF) is a biopharmaceutical company that develops and commercializes medicines for severe and chronic diseases globally. While Eli Lilly and Company (NYSE:LLY) discovers, develops, and markets human pharmaceuticals internationally.

While we acknowledge the potential of CAMRF to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than CAMRF and that has 100x upside potential, check out our report about the cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.